Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RYTM
stocks logo

RYTM

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
43.72M
+50.34%
--
--
46.92M
+41.12%
--
--
51.42M
+22.93%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Rhythm Pharmaceuticals, Inc. (RYTM) for FY2025, with the revenue forecasts being adjusted by -4.85% over the past three months. During the same period, the stock price has changed by 15.00%.
Revenue Estimates for FY2025
Revise Downward
down Image
-4.85%
In Past 3 Month
Stock Price
Go Up
up Image
+15.00%
In Past 3 Month
12 Analyst Rating
up Image0
Wall Street analysts forecast RYTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RYTM is 83.42 USD with a low forecast of 72.00 USD and a high forecast of 94.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 66.390
sliders
Low
72.00
Averages
83.42
High
94.00
up Image0
Current: 66.390
sliders
Low
72.00
Averages
83.42
High
94.00
Stifel
Paul Matteis
Buy
maintain
$78 -> $94
2025-05-29
Reason
Stifel
Paul Matteis
Price Target
$78 -> $94
2025-05-29
maintain
Buy
Reason
B of A Securities
Tazeen Ahmad
Strong Buy
Maintains
$63 → $68
2025-04-10
Reason
B of A Securities
Tazeen Ahmad
Price Target
$63 → $68
2025-04-10
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$70 → $80
2025-04-08
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$70 → $80
2025-04-08
Reiterates
Strong Buy
Reason
Canaccord Genuity
Whitney Ijem
Strong Buy
Maintains
$81 → $92
2025-04-08
Reason
Canaccord Genuity
Whitney Ijem
Price Target
$81 → $92
2025-04-08
Maintains
Strong Buy
Reason
Canaccord raised the firm's price target on Rhythm Pharmaceuticals to $92 from $81 and keeps a Buy rating on the shares. The firm updated its model on the back of positive setmelanotide Ph3 data for acquired HO. Based on the primary endpoint result of -19.8% placebo adjusted BMI reduction from baseline (Pless than0.0001), wthey are increasing their POS in both the US and Europe to 100% versus. 80% previously.
Needham
Joseph Stringer
Strong Buy
Reiterates
$66
2025-04-08
Reason
Needham
Joseph Stringer
Price Target
$66
2025-04-08
Reiterates
Strong Buy
Reason
Wells Fargo
Derek Archila
Buy
Maintains
$80 → $91
2025-04-07
Reason
Wells Fargo
Derek Archila
Price Target
$80 → $91
2025-04-07
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Rhythm Pharmaceuticals Inc (RYTM.O) is -26.09, compared to its 5-year average forward P/E of -10.97. For a more detailed relative valuation and DCF analysis to assess Rhythm Pharmaceuticals Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.97
Current PE
-26.09
Overvalued PE
-4.41
Undervalued PE
-17.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.69
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.41
Undervalued EV/EBITDA
-13.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
50.50
Current PS
0.00
Overvalued PS
146.96
Undervalued PS
-45.97

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 288.14% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

RYTM News & Events

Events Timeline

(ET)
2025-06-25
08:04:43
Rhythm Pharmaceuticals announces three data abstracts accepted for ENDO 2025
select
2025-05-14 (ET)
2025-05-14
08:17:00
Rhythm Pharmaceuticals announces presentations on setmelanotide
select
2025-05-07 (ET)
2025-05-07
07:10:13
Rhythm Pharmaceuticals reports Q1 EPS (81c), consensus (68c)
select
Sign Up For More Events
Sign Up For More Events

News

Preview
8.0
07-03NASDAQ.COM
Notable Wednesday Option Activity: RYTM, NCLH, DKNG

  • Norwegian Cruise Line Options Activity: Norwegian Cruise Line Holdings Ltd (NCLH) experienced significant options trading with 95,011 contracts, particularly the $20 strike call option expiring on September 19, 2025, which saw 46,950 contracts traded.

  • DraftKings Options Activity: DraftKings Inc (DKNG) also had notable options trading with 53,747 contracts, highlighted by the $44 strike call option expiring on July 11, 2025, where 5,828 contracts were traded.

Preview
4.0
06-27Benzinga
8 Analysts Have This To Say About Rhythm Pharmaceuticals

  • Analyst Ratings Overview: Recent evaluations of Rhythm Pharmaceuticals by 8 analysts show a mix of bullish and somewhat bullish sentiments, with an average 12-month price target increase to $80.88 from $73.50, reflecting positive market expectations.

  • Company Performance Insights: Rhythm Pharmaceuticals has demonstrated significant revenue growth of approximately 25.94% and maintains a low debt-to-equity ratio, although it faces challenges with negative return metrics such as ROE and ROA.

Preview
6.5
06-10NASDAQ.COM
Analysts Forecast 16% Upside For The Holdings of SMLF

  • ETF Analyst Target Prices: The iShares U.S. Small-Cap Equity Factor ETF (SMLF) has an implied analyst target price of $77.86 per unit, indicating a potential upside of 16.40% from its current trading price of $66.89.

  • Notable Holdings with Upside Potential: Key underlying holdings such as Klaviyo Inc, Rhythm Pharmaceuticals Inc, and MakeMyTrip Ltd show significant upside potential based on analyst targets, with expected increases ranging from 17.51% to 24.42%.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Rhythm Pharmaceuticals Inc (RYTM) stock price today?

The current price of RYTM is 66.39 USD — it has increased 0.94 % in the last trading day.

arrow icon

What is Rhythm Pharmaceuticals Inc (RYTM)'s business?

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.

arrow icon

What is the price predicton of RYTM Stock?

Wall Street analysts forecast RYTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RYTM is 83.42 USD with a low forecast of 72.00 USD and a high forecast of 94.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Rhythm Pharmaceuticals Inc (RYTM)'s revenue for the last quarter?

Rhythm Pharmaceuticals Inc revenue for the last quarter amounts to 32.70M USD, increased 25.94 % YoY.

arrow icon

What is Rhythm Pharmaceuticals Inc (RYTM)'s earnings per share (EPS) for the last quarter?

Rhythm Pharmaceuticals Inc. EPS for the last quarter amounts to -0.81 USD, decreased -65.53 % YoY.

arrow icon

What changes have occurred in the market's expectations for Rhythm Pharmaceuticals Inc (RYTM)'s fundamentals?

The market is revising Downward the revenue expectations for Rhythm Pharmaceuticals, Inc. (RYTM) for FY2025, with the revenue forecasts being adjusted by -4.85% over the past three months. During the same period, the stock price has changed by 15.00%.
arrow icon

How many employees does Rhythm Pharmaceuticals Inc (RYTM). have?

Rhythm Pharmaceuticals Inc (RYTM) has 283 emplpoyees as of July 08 2025.

arrow icon

What is Rhythm Pharmaceuticals Inc (RYTM) market cap?

Today RYTM has the market capitalization of 4.22B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free